Status epilepticus (SE) is one of the most frequent neurological emergencies with an incidence of 20/100,000 per year and a mortality between 3% and 40% depending on etiology, age, SE type and duration. Generalized convulsive forms of SE (GTCSE), in particular, require aggressive treatment. Presently, only 55—80% of cases of GTCSE are controlled by initial therapy. Therefore, there is a need for new options for the treatment of SE. Here we review the current standard treatment including recent advances and provide a summary of preclinical and clinical data regarding treatment options which may become available in the near future. The initial treatment of SE usually consists of a benzodiazepine (preferably lorazepam 0.1 mg/kg) followed by phenytoin or fosphenytoin or valproic acid (where approved for SE therapy). With intravenous formulations of levetiracetam, available since 2006, and lacosamide, which is expected for autumn of 2008, new treatment options have become available, that should be evaluated in prospective controlled trials. If SE remains refractory, the induction of general anaesthesia using propofol, midazolam, thiopental, or pentobarbital is warranted in GTCSE.
Treatment of convulsive status epilepticus. ( 1993) Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA270: 854-859.
2.
Alldredge, B.K., Gelb, A.M., Isaacs, S.M., Corry, M.D., Allen, F., Ulrich, S. et al. (2001) A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med345: 631-637.
3.
Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Perucca, E. and Tomson, T. (2007) Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res73: 1-52.
4.
Biton, V., Rosenfeld, W.E., Whitesides, J., Fountain, N.B., Vaiciene, N. and Rudd, GD (2008) Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia49: 418-424.
5.
Bleck, T.P. (1993) Advances in the management of refractory status epilepticus. Crit Care Med. 21: 955-957.
6.
Bleck, T.P. (2005) Refractory status epilepticus. Curr.Opin.Crit Care11: 117-120.
7.
Browne, T.R., Kugler, A.R. and Eldon, M.A. (1996) Pharmacology and pharmacokinetics of fosphenytoin . Neurology46: S3-S7.
8.
Burneo, J.G., Anandan, J.V. and Barkley, G.L. (2001) A prospective study of the incidence of the purple glove syndrome. Epilepsia42: 1156-1159.
9.
Chin, R.F., Neville, B.G., Peckham, C., Bedford, H., Wade, A. and Scott, R.C. (2006) Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet368: 222-229.
10.
Claassen, J., Hirsch, L.J., Emerson, R.G. and Mayer, S.A. (2002) Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia43: 146-153.
11.
Coeytaux, A., Jallon, P., Galobardes, B. and Morabia, A. (2000) Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology55: 693-697.
12.
Czapinski, P. and Terczynski, A. (1998) [Intravenous valproic acid administration in status epilepticus]. Neurol Neurochir Pol32: 11-22.
13.
DeLorenzo, R.J., Pellock, J.M., Towne, A.R. and Boggs, J.G. (1995) Epidemiology of status epilepticus. J Clin Neurophysiol12: 316-325.
14.
DeLorenzo, R.J., Waterhouse, E.J., Towne, A.R., Boggs, J.G., Ko, D., DeLorenzo, G.A. et al. (1998) Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia39: 833-840.
15.
Doty, P., Rudd, G.D., Stoehr, T. and Thomas, D. (2007) Lacosamide. Neurotherapeutics4: 145-148.
16.
Dreifuss, F.E., Rosman, N.P., Cloyd, J.C., Pellock, J.M., Kuzniecky, R.I., Lo, W.D. et al. (1998) A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med338: 1869-1875.
17.
Eldon, M.A. and Loewen, G. (1993) Pharmacokinetics and tolerance of fosphenytoin and phenytoin administration intravenously to healthy subjects. Can J Neurol Sci20: 5180.
18.
Fountain, N.B. (2000) Status epilepticus: risk factors and complications . Epilepsia41(Suppl 2): S23-S30.
19.
Del gado-Escueta, A.V., Wasterlain, C., Treiman, D.M. and Porter, R.J. (1982) Current concepts in neurology: management of status epilepticus. N Engl J Med306: 1337-1340.
20.
Garzon, E., Fernandes, R.M. and Sakamoto, A.C. (2003) Analysis of clinical characteristics and risk factors for mortality in human status epilepticus. Seizure12: 337-345.
21.
Gibbs, J.E. and Cock, H.R. (2007) Administration of levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model. Epilepsy Res73: 208-212.
22.
Gibbs, J.E., Walker, M.C. and Cock, H.R. (2006) Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia47: 469-478.
23.
Greenblatt, D.J. and Divoll, M. (1983) Diazepam versus lorazepam: relationship of drug distribution to duration of clinical action. Adv Neurol34: 487-491.
24.
Grosse, P., Rusch, L. and Schmitz, B. (1999) Pancreatitis complicating treatment of status epilepticus with intravenous valproate. Epilepsia40: S267.
25.
Hauser, W.A. (1990) Status epilepticus: epidemiologic considerations . Neurology40: 9-13.
26.
Hesdorffer, D.C., Logroscino, G., Cascino, G., Annegers, J.F. and Hauser, W.A. (1998) Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology50: 735-741.
27.
Holtkamp, M., Othman, J., Buchheim, K. and Meierkord, H. (2005) Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry76: 534-539.
28.
Jallon, P., Coeytaux, A., Galobardes, B. and Morabia, A. (1999) Incidence and case-fatality rate of status epilepticus in the Canton of Geneva. Lancet353: 1496.
29.
Jamerson, B.D., Dukes, G.E., Brouwer, K.L., Donn, K.H., Messenheimer, J.A. and Powell, J.R. (1994) Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy14: 47-52.
30.
Kaplan, P.W. (2000) Prognosis in nonconvulsive status epilepticus. Epileptic Disord2: 185-193.
31.
Kilarski, D.J., Buchanan, C. and Von Behren, L. (1984) Soft-tissue damage associated with intravenous phenytoin. N Engl J Med311: 1186-1187.
32.
Knake, S., Gruener, J., Hattemer, K., Klein, K.M., Bauer, S., Oertel, W.H. et al. (2008) Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry79: 588-589.
33.
Knake, S., Rosenow, F., Vescovi, M., Oertel, W.H., Mueller, H.H., Wirbatz, A. et al. (2001) Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia42: 714-718.
34.
Krauss, G., Ben-Menache, M.E., Mameniskiene, R., Vaiciene, N., Brock, M., Whitesides, J. et al. (2007). Intravenous lacosamide as replacemant for oral lacosamide in subjects with partial seizure onset: a multicenter, open-label, inpatient trial examining safety and tolerability of 10- and 15-minute infusions . Poster presented at the Annual Meeting of the American Epilepsy Society.
35.
Krishnamurthy, K.B. and Drislane, F.W. (1996) Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia37: 863-867.
36.
Leppik, I.E., Derivan, A.T., Homan, R.W., Walker, J., Ramsay, R.E. and Patrick, B. (1983) Double-blind study of lorazepam and diazepam in status epilepticus. JAMA249: 1452-1454.
37.
Limdi, N.A., Shimpi, A.V., Faught, E., Gomez, C.R. and Burneo, J.G. (2005) Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology64: 353-355.
38.
Logroscino, G., Hesdorffer, D.C., Cascino, G., Annegers, J.F. and Hauser, W.A. (1997) Short-term mortality after a first episode of status epilepticus. Epilepsia38: 1344-1349.
39.
Lowenstein, D.H. and Alldredge, B.K. (1993) Status epilepticus at an urban public hospital in the 1980s. Neurology43: 483-488.
40.
Lowenstein, D.H. and Alldredge, B.K. (1998) Status epilepticus. N Engl J Med338: 970-976.
41.
Lukyanetz, E.A., Shkryl, V.M. and Kostyuk, P.G. (2002) Selective blockade of N-type calcium channels by levetiracetam. Epilepsia43: 9-18.
42.
Mayer, S.A., Claassen, J., Lokin, J., Mendelsohn, F., Dennis, L.J. and Fitzsimmons, B.F. (2002) Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch.Neurol59: 205-210.
43.
Mazarati, A.M., Baldwin, R., Klitgaard, H., Matagne, A. and Wasterlain, C.G. (2004) Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res58: 167-174.
44.
Meierkord, H., Boon, P., Engelsen, B., Göcke, K., Shorvon, S., Tinuper, P. et al. (2006) EFNS guideline on the management of status epilepticus. Eur J Neurol13: 445-450.
45.
Minicucci, F., Muscas, G., Perucca, E., Capovilla, G., Vigevano, F. and Tinuper, P. (2006) Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia47(Suppl 50): 9-15.
46.
Mirsattari, S.M., Sharpe, M.D. and Young, G.B. (2004) Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol61: 1254-1259.
47.
Misra, U.K., Kalita, J. and Patel, R. (2006) Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology67: 340-342.
48.
O'Brien, T.J., Cascino, G.D., So, E.L. and Hanna, D.R. (1998) Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology51: 1034-1039.
49.
Olsen, K.B., Tauboll, E. and Gjerstad, L. (2007) Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurol Scand Suppl187: 51-54.
50.
Prasad, K., Al Roomi, K., Krishnan, P.R. and Sequeira, R. (2005) Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev (4): CD003723.
51.
Ramael, S., Daoust, A., Otoul, C., Toublanc, N., Troenaru, M., Lu, Z.S. et al. (2006a) Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia47: 1128-1135.
52.
Ramael, S., De, S.F., Toublanc, N., Otoul, C., Boulanger, P., Riethuisen, J.M. et al. (2006b) Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther28: 734-744.
53.
Ramsay, R.E., Philbrook, B. and Martinez, D. (1995) A double-blind, randomized safety comparison of rapidly infused intravenous loading doses of fosphenytoin vs phenytoin. Epilepsia36: S90.
54.
Rao, V.K., Feldman, P.D. and Dibbell, D.G. (1988) Extravasation injury to the hand by intravenous phenytoin. Report of three cases. J Neurosurg68: 967-969.
55.
Rosenow, F., Arzimanoglou, A. and Baulac, M. (2002) Recent developments in treatment of status epilepticus: a review. Epileptic Disord4(Suppl 2): S41-S51.
56.
Rosenow, F., Hamer, H.M. and Knake, S. (2007) The epidemiology of convulsive and nonconvulsive status epilepticus. Epilepsia48(Suppl 8): 82-84.
57.
Rossetti, A.O. (2007) Which anesthetic should be used in the treatment of refractory status epilepticus? Epilepsia48(Suppl 8): 52-55.
58.
Rossetti, A.O., Logroscino, G. and Bromfield, E.B. (2005) Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol62: 1698-1702.
59.
Schulze-Bonhage, A., Hefft, S. and Oehl, B. (2007) Termination of complex partial status epilepticus by intravenous levetiracetam - a case report. J Neurol Neurosurg Psychiatry Epub ahead, Mar 2007; doi:10.1136/jnnp.2006.113951.
60.
Sheth, R.D. and Gidal, B.E. (1998) Refractory status epilepticus: response to ketamine . Neurology51: 1765-1766.
61.
Sinha, S. and Naritoku, D.K. (2000) Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology55: 722-724.
62.
Stecker, M.M., Kramer, T.H., Raps, E.C., O'Meeghan, R., Dulaney, E. and Skaar, D.J. (1998) Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia39: 18-26.
63.
Stohr, T., Baldwin, R., Walton, N. and Westerlain, C. (2003) SPM 927 is Anticonvulsive and neuroprotective in rat models for self-sustaining status epilepticus. Poster presented at the American Epilepsy Society meeting 2003 in Boston. Ref Type: Abstract.
64.
Stohr, T., Krause, E. and Selve, N. (2006) Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain10: 241-249.
65.
Stohr, T., Kupferberg, H.J., Stables, J.P., Choi, D., Harris, R.H., Kohn, H. et al. (2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res74: 147-154.
66.
Stohr, T. and Westerlain, C. (2006) Lacosamide in in vitro and in vivo animal models for Neuroprotection. Poster presented at the American Epilepsy Society Meeting 2006. Ref Type: Abstract.
67.
Tomson, T. (2000) Mortality in epilepsy. J Neurol247: 15-21.
68.
Towne, A.R., Pellock, J.M., Ko, D. and DeLorenzo, R.J. (1994) Determinants of mortality in status epilepticus . Epilepsia35: 27-34.
69.
Treiman, D.M. (1998) Clinical trials for status epilepticus. Adv Neurol76: 173-178.
70.
Treiman, D.M., Meyers, P.D., Walton, N.Y., Collins, J.F., Colling, C., Rowan, A.J. et al. (1998) A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med339: 792-798.
71.
Uberall, M.A., Trollmann, R., Wunsiedler, U. and Wenzel, D. (2000) Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology54: 2188-2189.
72.
Uusimaa, J., Hinttala, R., Rantala, H., Päivärinta, M., Herra, R., Röyttä, M. et al. (2008) Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia.
73.
Velioglu, S.K. and Gazioglu, S. (2007) Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy. Acta Neurol Scand116: 128-132.
74.
Venkataraman, V. and Wheless, J.W. (1999) Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res35: 147-153.
75.
Vignatelli, L., Rinaldi, R., Galeotti, M., de, C.P. and D'Alessandro, R. (2005) Epidemiology of status epilepticus in a rural area of northern Italy: a 2-year population-based study. Eur J Neurol12: 897-902.
76.
Vignatelli, L., Tonon, C. and D'Alessandro, R. (2003) Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy. Epilepsia44: 964-968.
77.
Walton, N.Y., Uthman, B.M., El Yafi, K., Kim, J.M. and Treiman, D.M. (1999) Phenytoin penetration into brain after administration of phenytoin or fosphenytoin. Epilepsia40: 153-156.
78.
Wu, Y.W., Shek, D.W., Garcia, P.A., Zhao, S. and Johnston, S.C. (2002) Incidence and mortality of generalized convulsive status epilepticus in California. Neurology58: 1070-1076.
79.
Yaffe, K. and Lowenstein, D.H. (1993) Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology43: 895-900.
